中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系

黄蓉 倪加加 高毅

胡辉, 黄贝贝, 宁玲, 江守伟, 沈强, 刘磊, 李磊. HBV相关慢加急性肝衰竭患者短期预后预测模型的建立与评价[J]. 临床肝胆病杂志, 2020, 36(1): 123-127. DOI: 10.3969/j.issn.1001-5256.2020.01.027.
引用本文: 胡辉, 黄贝贝, 宁玲, 江守伟, 沈强, 刘磊, 李磊. HBV相关慢加急性肝衰竭患者短期预后预测模型的建立与评价[J]. 临床肝胆病杂志, 2020, 36(1): 123-127. DOI: 10.3969/j.issn.1001-5256.2020.01.027.
Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2020, 36(1): 123-127. DOI: 10.3969/j.issn.1001-5256.2020.01.027.
Citation: Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2020, 36(1): 123-127. DOI: 10.3969/j.issn.1001-5256.2020.01.027.

肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系

DOI: 10.3969/j.issn.1001-5256.2018.06.041
基金项目: 

国家自然科学基金(81470875); 

详细信息
  • 中图分类号: R735.7

The association between the intestinal microbiota-lipopolysaccharide-Toll-like receptor 4 axis and hepatocellular carcinoma

Research funding: 

 

  • 摘要: 肝细胞癌是各种慢性肝病终末期的主要并发症,研究表明肝病患者普遍存在肠道屏障破坏和肠道菌群紊乱,导致肠道细菌移位,发生内毒素血症。Toll样受体4是肝内一种模式识别受体,能够结合内毒素中的活性成分——脂多糖,通过胞内一系列信号转导途径导致免疫炎症反应,最终促进肝纤维化和肿瘤发生。综述了肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌发病机制相关研究进展。

     

  • [1]LUO J, JIN F.Recent advances in understanding the impact of intestinal microbiota on host behavior[J].Chin Sci Bull, 2014, 59 (22) :2169-2190. (in Chinese) 罗佳, 金锋.肠道菌群影响宿主行为的研究进展[J].科学通报, 2014, 59 (22) :2169-2190.
    [2]YU LX, SCHWABE RF.The gut microbiome and liver cancer:mechanisms and clinical translation[J].Nat Rev Gastroenterol Hepatol, 2017, 14 (9) :527-539.
    [3]KIZILTAS S.Toll-like receptors in pathophysiology of liver diseases[J].World J Hepatol, 2016, 8 (32) :1354-1369.
    [4]WEI XP, GAO X, MA YJ.Relationship between small intestinal bacterial overgrowth and severity of with hepatitis B cirrhosis[J].J Clin Hepatol, 2016, 32 (4) :716-719. (in Chinese) 魏新朋, 高晓, 马英杰.乙型肝炎肝硬化患者小肠细菌过度生长与疾病严重程度的相关性[J].临床肝胆病杂志, 2016, 32 (4) :716-719.
    [5]BENTEN D, WIEST R.Gut microbiome and intestinal barrier failure——the"Achilles heel"in hepatology?[J].J Hepatol, 2012, 56 (6) :1221-1223.
    [6]WU ZW, XU KJ, LI LJ, et al.Investigation of intestinal bacterial translocation in 78 patients with cirrhosis after liver transplantation[J].Chin J Surg, 2006, 44 (21) :1456-1459. (in Chinese) 吴仲文, 徐凯进, 李兰娟, 等.78例肝硬化患者肠道细菌易位及其相关性研究[J].中华外科杂志, 2006, 44 (21) :1456-1459.
    [7]RACANELLI V, REHERMANN B.The liver as an immunological organ[J].Hepatology, 2006, 43 (2 Suppl 1) :s54-s62.
    [8]TAKEDA K, KAISHO T, AKIRA S.Toll-like receptors[J].Annu Rev Immunol, 2003, 21 (1) :335-376.
    [9]DAPITO DH, MENCIN A, GWAK GY, et al.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J].Cancer Cell, 2012, 21 (4) :504-516.
    [10]YOON HY, YI HY.Liver cirrhosis mortality in the United States, 1970-2007 surveillance report#88:NIAAA homepage 2010[EB/OL].http://pubs.niaaa.nih.gov/publications/surveillance88/Cirr07.htm, 2017-12-7.
    [11]REHM J, MATHERS C, POPOVA S, et al.Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders[J].Lancet, 2009, 373 (9682) :2223-2233.
    [12]SANYAL AJ, YOON SK, LENCIONI R.The etiology of hepatocellular carcinoma and consequences for treatment[J].Oncologist, 2010, 15 (Suppl 4) :14-22.
    [13]LIPPAI D, BALA S, CATALANO D, et al.Micro-RNA-155deficiency prevents alcohol-induced serum endotoxin increase and small bowel inflammation in mice[J].Alcohol Clin Exp Res, 2014, 38 (8) :2217-2224.
    [14]PRADERE JP, TROEGER JS, DAPITO DH, et al.Toll-like receptor 4 and hepatic fibrogenesis[J].Semin Liver Dis, 2010, 30 (3) :232-244.
    [15]SZABO G.Gut-liver axis in alcoholic liver disease[J].Gastroenterology, 2015, 148 (1) :30-36.
    [16]UESUGI T, FROH M, ARTEEL GE, et al.Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice[J].Hepatology, 2001, 34 (1) :101-108.
    [17]ADACHI Y, MOORE LE, BRADFORD BU, et al.Antibiotics prevent liver injury in rats following long-term exposure to ethanol[J].Gastroenterology, 1995, 108 (1) :218-224.
    [18]FAN JG, FARRELL GC.Epidemiology of non-alcoholic fatty liver disease in China[J].J Hepatol, 2009, 50 (1) :204-210.
    [19]MICHELOTTI GA, MACHADO MV, DIEHL AM.NAFLD, NASH and liver cancer[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :656.
    [20]STREBA LA, VERE CC, ROGOVEANU I, et al.Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma:An open question[J].World J Gastroenterol, 2015, 21 (14) :4103-4110.
    [21]ZHOU D, PAN Q, SHEN F, et al.Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J].Sci Rep, 2017, 7 (1) :1529.
    [22]SPRUSS A, KANURI G, WAGNERBERGER S, et al.Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice[J].Hepatology, 2009, 50 (4) :1094-1104.
    [23]PAPPO I, BERCOVIER H, BERRY EM, et al.Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide[J].JPEN J Parenter Enteral Nutr, 1992, 16 (6) :529-532.
    [24]PAPPO I, BECOVIER H, BERRY EM, et al.Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat[J].J Surg Res, 1991, 51 (2) :106-112.
    [25]DRENICK EJ, FISLER J, JOHNSON D.Hepatic steatosis after intestinal bypass——prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition[J].Gastroenterology, 1982, 82 (3) :535-548.
    [26]MIELE L, VALENZA V, LA TORRE G, et al.Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease[J].Hepatology, 2009, 49 (6) :1877-1887.
    [27]BROERING R, LU M, SCHLAAK JF.Role of Toll-like receptors in liver health and disease[J].Clin Sci (Lond) , 2011, 121 (10) :415-426.
    [28]SOARES JB, PIMENTEL-NUNES P, RONCON-ALBUQUERQUE R, et al.The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases[J].Hepatol Int, 2010, 4 (4) :659-672.
    [29]KAO JH, CHEN DS.Global control of hepatitis B virus infection[J].Lancet Infect Dis, 2002, 2 (7) :395-403.
    [30]CHEN DS.Fighting against viral hepatitis:Lessons from Taiwan[J].Hepatology, 2011, 54 (2) :381-392.
    [31]CHEN MM, ZHENG JS, LIU YY, et al.Changes of intestinal microbiota in patients with chronic hepatitis B and liver cirrhosis[J].Acta Univ Med Anhui, 2015, 50 (5) :648-652. (in Chinese) 陈萌萌, 郑吉顺, 刘艳艳, 等.慢性乙型肝炎以及肝硬化患者肠道微生物研究[J].安徽医科大学学报, 2015, 50 (5) :648-652.
    [32]LI LJ, WU ZW, MA WH, et al.Changes in intestinal microflora in patients with chronic severe hepatitis[J].Chin Med J, 2001, 114 (8) :86-89. (in Chinese) 李兰娟, 吴仲文, 马伟杭, 等.慢性重型肝炎患者肠道菌群变化及其作用的研究 (英文) [J].中华医学杂志, 2001, 114 (8) :86-89.
    [33]DOLGANIUC A, NORKINA O, KODYS K, et al.Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection[J].Gastroenterology, 2007, 133 (5) :1627-1636.
    [34] JIANG FM, LI XF, CHENG SQ, et al.Clinical significance of expression of TLR3 and TLR4 in liver tissue of patients with chronic hepatitis B[J].Int J Virol, 2017, 24 (3) :209-212. (in Chinese) 蒋福明, 李秀芬, 程书权, 等.慢性乙型肝炎患者肝组织Toll样受体3、4表达及其临床意义[J].国际病毒学杂志, 2017, 24 (3) :209-212.
    [35]SOARES JB, PIMENTEL-NUNES P, AFONSO L, et al.Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence[J].Innate Immun, 2012, 18 (5) :700-708.
    [36]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.
    [37]YU LX, YAN HX, LIU Q, et al.Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents[J].Hepatology, 2010, 52 (4) :1322-1333.
    [38]JING YY, HAN ZP, SUN K, et al.Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide[J].BMC Med, 2012, 10:98.
    [39]MACHIDA K, TSUKAMOTO H, MKRTCHYAN H, et al.Tolllike receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog[J].Proc Natl Acad Sci U S A, 2009, 106 (5) :1548-1553.
    [40]ZHANG HL, YU LX, YANG W, et al.Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J].J Hepatol, 2012, 57 (4) :803-812.
    [41]LI J, SUNG CY, LEE N, et al.Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J].Proc Natl Acad Sci U S A, 2016, 113 (9) :e1306-e1315.
  • 期刊类型引用(25)

    1. 陈炜. 终末期肝病模型联合血清钠评分对肝衰竭患者短期预后的预测价值. 川北医学院学报. 2024(02): 247-251 . 百度学术
    2. 王学英. MELD-Na评分联合NLR预测肝硬化食管胃静脉曲张破裂出血后再出血的临床价值. 罕少疾病杂志. 2024(05): 70-72 . 百度学术
    3. 林小洪,吴文楠,荀振. 血小板-白蛋白-胆红素评分与肝硬化患者肝功能Child-Turcotte-Pugh分级的相关性分析. 福建医科大学学报. 2024(01): 37-43 . 百度学术
    4. 孙玉,秦维,王丹,郑艳丽,霍玉玲. 前白蛋白及纤维蛋白原水平与代偿期肝硬化食管静脉曲张发生的关系. 中国肝脏病杂志(电子版). 2024(02): 7-12 . 百度学术
    5. 石红. 延续性护理服务方案对肝硬化食管胃静脉曲张内镜下精准断流术后的临床影响研究. 基层医学论坛. 2024(20): 114-116+142 . 百度学术
    6. 李欣忆,李娇娇,孙蔚. 肝硬化食管胃底静脉曲张破裂出血患者经颈静脉肝内门体分流术后发生显性肝性脑病的列线图预测模型建立及评价. 临床肝胆病杂志. 2024(08): 1605-1611 . 本站查看
    7. 杨丹,周健. 多种无创预测模型在肝硬化门静脉高压中的研究进展. 中国临床研究. 2024(11): 1778-1783 . 百度学术
    8. 陈刚,谷光丽,何映雪,唐尧. 血清表皮生长因子对肝硬化食管胃静脉曲张患者再出血的诊断价值分析. 转化医学杂志. 2024(10): 1698-1702 . 百度学术
    9. 喻雪珂,黎孟玲,彭思远,申月明,梁纶熙,曾亚. 食管胃底静脉曲张破裂出血对肝硬化患者1年死亡结局的影响及相关因素研究. 中国全科医学. 2023(14): 1745-1752 . 百度学术
    10. 郝艳萍,韩靓,仇晶辉,滕圣智,王建华. 乙肝肝硬化食管胃静脉曲张急性出血患者内镜下治疗后发生菌血症的危险因素分析. 中国消毒学杂志. 2023(03): 182-184 . 百度学术
    11. 顾达,童聪,赵祥安,向晓星. PC/SD、FIB-4指数、CTP评分、MELD评分、MELD-Na评分在预测肝硬化食管静脉曲张出血套扎术后1年内再出血的价值评估. 胃肠病学和肝病学杂志. 2023(03): 289-294 . 百度学术
    12. 朱会明,张华,张金荣,吴雪华,吴柳,刘义安. 肝硬化血瘀证患者食管胃底静脉曲张相关性研究. 中国中医急症. 2023(04): 665-668 . 百度学术
    13. 周苏云,周影,程新月. 肝硬化患者发生肝性脑病的影响因素分析及对预检分诊意义的探讨. 中西医结合护理(中英文). 2023(03): 130-132 . 百度学术
    14. 葛琴. 血府逐瘀汤联合双歧杆菌三联活菌治疗酒精性肝硬化的疗效研究. 中医临床研究. 2023(20): 142-145 . 百度学术
    15. 邱荣金,卢劲瑜,苏雪梅,郑凤祥,廖丽芳. 预防使用抗生素对食管胃静脉曲张内镜下治疗的影响评估. 中国现代药物应用. 2023(19): 99-101 . 百度学术
    16. 邢恩涛,赵孟杰,金鹏飞,武振东,刘志春. 肝硬化门静脉高压TIPS术后HVPG下降相关因素. 青岛大学学报(医学版). 2023(05): 759-762 . 百度学术
    17. 刘媛,徐建光,何雪云,万秀萍,林小花,王莉娟,郑临海. 血钙浓度联合MELD评分对肝硬化严重程度的预测价值. 浙江中西医结合杂志. 2022(02): 129-130+149 . 百度学术
    18. 张春燕,田正方,朱经科,晁燕茹. 肝硬化患者食管静脉曲张套扎术后再出血影响因素分析及干预对策. 黑龙江医药科学. 2022(02): 96-99 . 百度学术
    19. 俞斌,屠军,沈玉玲. AIMS65评分预测肝硬化食管胃底静脉曲张破裂出血患者死亡的价值. 胃肠病学和肝病学杂志. 2022(07): 737-742 . 百度学术
    20. 刘益,周自忠,刘刚,徐海荣. 食管胃底静脉曲张破裂出血患者急诊TIPS术后肝性脑病发生特征及危险因素分析. 肝脏. 2022(06): 658-661 . 百度学术
    21. 廖翔. 肝硬化患者SAAG与食管胃底静脉曲张破裂出血的关系研究. 现代诊断与治疗. 2022(11): 1646-1648+1692 . 百度学术
    22. 张春燕,田正方,朱经科,晁燕茹. 肝硬化患者食管静脉曲张套扎术后再出血影响因素分析. 黑龙江医药科学. 2022(05): 171-173 . 百度学术
    23. 曾伍姣,张知洪,陈令民,李亦明. 血管紧张素Ⅱ水平在肝硬化患者诊断中的应用及与MELD评分关系研究. 肝胆外科杂志. 2021(01): 60-63 . 百度学术
    24. 祝强,杨继敏,刘中亮. 八种评分系统对肝硬化失代偿期患者短期预后的预测价值. 中国医药科学. 2021(19): 18-22 . 百度学术
    25. 赵媛,赵明,范玉梅,邵建营. 失代偿期乙型肝炎肝硬化患者不同病毒学应答状态对生存率及肝癌患病率的影响. 中国实用医刊. 2020(23): 50-52 . 百度学术

    其他类型引用(9)

  • 加载中
计量
  • 文章访问数:  1567
  • HTML全文浏览量:  18
  • PDF下载量:  329
  • 被引次数: 34
出版历程
  • 收稿日期:  2017-12-11
  • 出版日期:  2018-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回